

Rowan University

Rowan Digital Works

Rowan-Virtua Research Day

23rd Annual Research Day

May 2nd, 12:00 AM

The Evolving Long-Term Outcome of Heart Transplantation in Amyloid Patients

Avish Jain

Rowan University

Sadia Dimbil

Ryan Levine

Michele Hamilton

Jon A. Kabashigawa

Follow this and additional works at: https://rdw.rowan.edu/stratford_research_day



Part of the [Hemic and Lymphatic Diseases Commons](#)


Let us know how access to this document benefits you - share your thoughts on our [feedback form](#).

Jain, Avish; Dimbil, Sadia; Levine, Ryan; Hamilton, Michele; and Kabashigawa, Jon A., "The Evolving Long-Term Outcome of Heart Transplantation in Amyloid Patients" (2019). *Rowan-Virtua Research Day*. 8. https://rdw.rowan.edu/stratford_research_day/2019/may2/8

This Poster is brought to you for free and open access by the Conferences, Events, and Symposia at Rowan Digital Works. It has been accepted for inclusion in Rowan-Virtua Research Day by an authorized administrator of Rowan Digital Works.




Background



Both amyloid light chain (AL) amyloidosis and transthyretin (TTR) amyloidosis are now expanding indications for heart transplantation (HTx)

In the past, AL amyloid, in particular, had been a contraindication to HTx given its suboptimal control, systemic nature & progression to other organs, pre-malignant character, recurrence in allograft/transplanted organ, and the increased risk for mortality.



Advanced ACM carries a poor prognosis!

Standard heart failure therapies have limited utility & can be harmful: including Beta-blockers, ACEIs, ARBs, Digoxin

Left Ventricular Assist Devices (LVADs) have had only isolated successes
- Use of these is often limited by RV dysfunction -> restrictive CM

Modern treatments including proteasome inhibitors (reversible, such as *Bortezomib*, or irreversible) combined with traditional chemotherapy drugs (such as *melphalan* or *dexamethasone*) have allowed amyloid patients to increasingly receive heart transplants

- Normalization of free-light chains
- Rapid hematological improvement
- Used for amyloidosis relapse post-HTx

Purpose

In past research, the 2-year survival rate of patients with cardiac amyloidosis is less than 20% without HTx compared to a survival rate of 60% after HTx

We sought to assess long-term post-transplant outcome in amyloid patients in the current era, using our patient population that underwent HTx for cardiac amyloidosis at our single center.

Methods

- **Between 2010 and 2015**, we assessed 45 Heart Transplant Pts:
 - All Amyloid (n=27) -> broken up into AL (n=5), TTR wt senile (n=10), TTR mutant (n=12)
 - Non-Amyloid Restrictive Control (n=18)
- **Endpoints included:**
 - Subsequent 3-year survival
 - Subsequent 3-year freedom from CAV (as defined by stenosis $\geq 30\%$ by angiography)
 - Subsequent 3-year freedom from non-fatal major adverse cardiac events (NF-MACE: myocardial infarction, new congestive heart failure, percutaneous coronary intervention, implantable cardioverter defibrillator/pacemaker implant, stroke).
 - Subsequent 3-year freedom from any-treated rejection, acute cellular rejection, and antibody-mediated rejection

Demographics & Outcomes

Demographics	All Amyloid (n=27)	Non-Amyloid Restrictive Control (n=18)	P-Value
Mean Recipient Age, Years \pm SD	66.6 \pm 7.6	47.8 \pm 14.3	<0.001
Mean Donor Age, Years \pm SD	35.3 \pm 11.7	34.2 \pm 10.2	0.768
Body Mass Index, Mean \pm SD	25.0 \pm 3.9	24.7 \pm 3.9	0.818
Female (%)	11.1%	61.1%	<0.001
Previous Pregnancy in Females (%)	66.7%	45.5%	0.514
Ischemic Time, Mean Mins \pm SD	144.1 \pm 47.5	157.1 \pm 59.2	0.420
Diabetes Mellitus (%)	22.2%	5.6%	0.130
Status 1 at Transplant (%)	74.1%	77.8%	0.777
Cytomegalovirus Mismatch (%)	22.2%	22.2%	1.000
Treated Hypertension (%)	43.5%	26.7%	0.293
Insertion of Mechanical Circulatory Support Device (%)	14.8%	5.6%	0.332
Prior Blood Transfusion (%)	30.4%	14.3%	0.266
Pre-Transplant PRA $\geq 10\%$ (%)	25.9%	27.8%	0.890
Pre-Transplant Creatinine, Mean \pm SD	1.5 \pm 0.7	1.4 \pm 1.0	0.629

Endpoints	All Amyloid (n=27)	Non-Amyloid Restrictive Control (n=18)	Log-Rank P-Value
3-Year Survival	88.9%	94.4%	0.883
3-Year Freedom from CAV	81.5%	88.9%	0.828
3-Freedom from NF-MACE	85.2%	100.0%	0.112
3-Freedom from Any-Treated Rejection	96.3%	94.4%	0.436
3-Year Freedom from Acute Cellular Rejection	96.3%	100.0%	0.535
3-Year Freedom from Antibody-Mediated Rejection	100.0%	94.4%	0.075

Endpoints	AL (n=5)	TTR wt senile (n=10)	TTR mutant (n=12)	Non-Amyloid Restrictive Control (n=18)	Log-Rank P-Value
3-Year Survival	100.0%	90.0%	83.3%	94.4%	0.790
3-Year Freedom from CAV	80.0%	80.0%	83.3%	88.9%	0.990
3-Freedom from NF-MACE	100.0%	90.0%	75.0%	100.0%	0.112
3-Freedom from Any-Treated Rejection	100.0%	100.0%	91.7%	94.4%	0.619
3-Year Freedom from Acute Cellular Rejection	100.0%	100.0%	91.7%	100.0%	0.518
3-Year Freedom from Antibody-Mediated Rejection	100.0%	100.0%	100.0%	94.4%	0.367

Results Summary

There was no significant difference between the All amyloid and restrictive non-amyloid patients with respect to 3-year survival and 3-year freedom from CAV, NF-MACE, and rejection.

Furthermore, there was no significant difference between the AL amyloid, TTR-wt, TTR-m, and restrictive non-amyloid patients with respect to 3-year survival and 3-year freedom from CAV, NF-MACE, and rejection.

Endomyocardial biopsies post-transplant did not show amyloid.

Conclusion

- In the current era, both AL & TTR amyloid patients have acceptable mid-term outcome after HTx.
- Larger numbers & longer follow-ups are needed to confirm findings.
- Need to consider sociological & economical components to analyze the capability of patients to undergo & afford such extensive Tx.
- **RNA TAFAMIDIS THERAPY, Doxycycline, Green Tea for now!**